APA (7th ed.) Citation

McIlroy, G., Lax, S., Gaskell, C., Jackson, A., Rhodes, M., Seale, T., . . . Bishton, M. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): Study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer, 24(1), 1. https://doi.org/10.1186/s12885-024-12112-0

Chicago Style (17th ed.) Citation

McIlroy, Graham, et al. "Investigator Choice of Standard Therapy Versus Sequential Novel Therapy Arms in the Treatment of Relapsed Follicular Lymphoma (REFRACT): Study Protocol for a Multi-centre, Open-label, Randomised, Phase II Platform Trial." BMC Cancer 24, no. 1 (2024): 1. https://doi.org/10.1186/s12885-024-12112-0.

MLA (9th ed.) Citation

McIlroy, Graham, et al. "Investigator Choice of Standard Therapy Versus Sequential Novel Therapy Arms in the Treatment of Relapsed Follicular Lymphoma (REFRACT): Study Protocol for a Multi-centre, Open-label, Randomised, Phase II Platform Trial." BMC Cancer, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12885-024-12112-0.